CA3220428A1 - Methods of use of anti-sortilin antibodies - Google Patents

Methods of use of anti-sortilin antibodies

Info

Publication number
CA3220428A1
CA3220428A1 CA3220428A CA3220428A CA3220428A1 CA 3220428 A1 CA3220428 A1 CA 3220428A1 CA 3220428 A CA3220428 A CA 3220428A CA 3220428 A CA3220428 A CA 3220428A CA 3220428 A1 CA3220428 A1 CA 3220428A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
hvr
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3220428A
Other languages
English (en)
French (fr)
Inventor
Robert Paul
Sam Jackson
Omer Rizwan SIDDIQUI
Michael F. Ward
Felix Leejia YEH
Julie Y. HUANG
Whedy Wang
Yijie LIAO
Brian C. MANGAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alector LLC
Original Assignee
Alector LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector LLC filed Critical Alector LLC
Publication of CA3220428A1 publication Critical patent/CA3220428A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3220428A 2021-06-08 2022-06-08 Methods of use of anti-sortilin antibodies Pending CA3220428A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163208238P 2021-06-08 2021-06-08
US63/208,238 2021-06-08
US202163209360P 2021-06-10 2021-06-10
US63/209,360 2021-06-10
US202163225916P 2021-07-26 2021-07-26
US63/225,916 2021-07-26
US202163277069P 2021-11-08 2021-11-08
US63/277,069 2021-11-08
US202263304522P 2022-01-28 2022-01-28
US63/304,522 2022-01-28
US202263311379P 2022-02-17 2022-02-17
US63/311,379 2022-02-17
PCT/US2022/072827 WO2022261648A2 (en) 2021-06-08 2022-06-08 Methods of use of anti-sortilin antibodies

Publications (1)

Publication Number Publication Date
CA3220428A1 true CA3220428A1 (en) 2022-12-15

Family

ID=84426402

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3220428A Pending CA3220428A1 (en) 2021-06-08 2022-06-08 Methods of use of anti-sortilin antibodies

Country Status (6)

Country Link
US (1) US20240132597A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526060A (cg-RX-API-DMAC7.html)
BR (1) BR112023025188A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220428A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022261648A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119679944A (zh) * 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
EP3983441A1 (en) * 2019-06-11 2022-04-20 Alector LLC Anti-sortilin antibodies for use in therapy

Also Published As

Publication number Publication date
JP2024526060A (ja) 2024-07-17
EP4351728A4 (en) 2025-08-27
WO2022261648A3 (en) 2023-01-19
EP4351728A2 (en) 2024-04-17
US20240132597A1 (en) 2024-04-25
BR112023025188A2 (pt) 2024-02-27
WO2022261648A2 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
US12358991B2 (en) Anti-Sortilin antibodies and methods of use thereof
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
US12319734B2 (en) Anti-TMEM106B antibodies and methods of use thereof
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
US20240101681A1 (en) Methods of use of anti-sortilin antibodies
CN117794573A (zh) 抗分拣蛋白抗体的使用方法
EA051513B1 (ru) Способы применения антител к сортилину
HK40099363A (en) Anti-sortilin antibodies and methods of use thereof
CN116964089A (zh) 使用抗分拣蛋白抗体的方法
EA046146B1 (ru) Антитела против сортилина и способы их применения
HK40025057B (en) Anti-sortilin antibodies and methods of use thereof
HK40025057A (en) Anti-sortilin antibodies and methods of use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523